These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427 [No Abstract] [Full Text] [Related]
6. [Incretin related agents for treatment of diabetes mellitus]. Miyagawa J; Miuchi M; Nanba M Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544 [No Abstract] [Full Text] [Related]
7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128 [TBL] [Abstract][Full Text] [Related]
8. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749 [TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Bailey CJ; Green BD; Flatt PR Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618 [TBL] [Abstract][Full Text] [Related]
10. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784 [TBL] [Abstract][Full Text] [Related]
11. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database]. Umetsu R; Nishibata Y; Abe J; Suzuki Y; Hara H; Nagasawa H; Kinosada Y; Nakamura M Yakugaku Zasshi; 2014; 134(2):299-304. PubMed ID: 24492232 [TBL] [Abstract][Full Text] [Related]
13. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. Abel T; Fehér J Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Scheen AJ Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1265-76. PubMed ID: 20707611 [TBL] [Abstract][Full Text] [Related]
15. From insulin to incretins: a report from the 67th scientific sessions of the American Diabetes Association. Rabasseda X Timely Top Med Cardiovasc Dis; 2007 Aug; 11():E21. PubMed ID: 18297152 [No Abstract] [Full Text] [Related]
16. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. Tanaka K; Ogawa Y; Shimada S J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936 [No Abstract] [Full Text] [Related]
17. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500 [TBL] [Abstract][Full Text] [Related]
18. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial". Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890 [TBL] [Abstract][Full Text] [Related]